Close this search box.

AI-guided antibody designer BigHat taps J&J as latest partner as internal pipeline advances


Still years away from the clinic, the biotech now has four deals with larger pharmas that are informing decisions around its wholly-owned programs

By Paul Bonanos, Director of Biopharma Intelligence

April 24, 2024 12:03 PM UTC

A deal with J&J to create optimized antibodies for neurological disorders is the latest step in BigHat’s evolution as it moves its internal pipeline of AI-designed biologics toward the clinic.

The agreement with the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) is the fourth with a large pharma for BigHat Biosciences Inc., after deals with AbbVie Inc. (NYSE:ABBV), Amgen Inc. (NASDAQ:AMGN) and Merck & Co. Inc. (NYSE:MRK). Financial terms and targets are undisclosed…